Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246586307> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W4246586307 endingPage "75" @default.
- W4246586307 startingPage "70" @default.
- W4246586307 abstract "Pharmacological inhibition of the kinase activity of JAK proteins can interfere with the signalling of immunomodulatory cytokines and block the constitutive activation of the JAK-STAT pathway that characterizes certain malignancies, including chronic myeloproliferative neoplasms. JAK inhibitors may, therefore, be useful to treat malignancies as well as inflammatory or immune disorders. Currently, the most significant advances have been made in the treatment of myelofibrosis, where these drugs may lead to a remarkable improvement in the control of hyperproliferative manifestations. However, available data suggest that this treatment is not curative of myelofibrosis. In general, JAK2 inhibition induces cytopaenias, with this being considered a class side-effect. By contrast, the extrahaematologic toxicity profile varies significantly among the different JAK inhibitors. At present, there are several clinical trials evaluating the combination of ruxolitinib with other drugs, in order to improve its therapeutic activity as well as reducing haematologic toxicity. La inhibición farmacológica de la actividad cinasa de las proteínas JAK permite interferir la señalización de las citocinas inmunomoduladoras y bloquear la activación constitutiva de la vía JAK-STAT que caracteriza a ciertas neoplasias, en particular a las mieloproliferativas crónicas. Así, los inhibidores de JAK pueden ser útiles tanto para el tratamiento del cáncer como para el de enfermedades de origen inflamatorio o inmunitario. Hasta el momento, los avances más significativos se han dado en la mielofibrosis, donde permiten un mejor control de las manifestaciones hiperproliferativas, si bien no parecen tener capacidad de erradicar la enfermedad. En general, la inhibición de JAK2 se asocia al desarrollo de citopenias, siendo este un efecto adverso de clase. En cambio, el perfil de toxicidad extrahematológica varía de un inhibidor a otro. Actualmente, se están explorando combinaciones de ruxolitinib con otros fármacos cara a potenciar la eficacia terapéutica y a reducir su toxicidad hematológica." @default.
- W4246586307 created "2022-05-12" @default.
- W4246586307 creator A5003330066 @default.
- W4246586307 creator A5042968949 @default.
- W4246586307 creator A5080986642 @default.
- W4246586307 date "2016-07-01" @default.
- W4246586307 modified "2023-10-16" @default.
- W4246586307 title "JAK2 inhibitors" @default.
- W4246586307 doi "https://doi.org/10.1016/j.medcle.2016.09.004" @default.
- W4246586307 hasPublicationYear "2016" @default.
- W4246586307 type Work @default.
- W4246586307 citedByCount "0" @default.
- W4246586307 crossrefType "journal-article" @default.
- W4246586307 hasAuthorship W4246586307A5003330066 @default.
- W4246586307 hasAuthorship W4246586307A5042968949 @default.
- W4246586307 hasAuthorship W4246586307A5080986642 @default.
- W4246586307 hasConcept C112392421 @default.
- W4246586307 hasConcept C126322002 @default.
- W4246586307 hasConcept C157333092 @default.
- W4246586307 hasConcept C170493617 @default.
- W4246586307 hasConcept C2776112149 @default.
- W4246586307 hasConcept C2780007613 @default.
- W4246586307 hasConcept C2780076729 @default.
- W4246586307 hasConcept C42362537 @default.
- W4246586307 hasConcept C502942594 @default.
- W4246586307 hasConcept C71924100 @default.
- W4246586307 hasConcept C98274493 @default.
- W4246586307 hasConceptScore W4246586307C112392421 @default.
- W4246586307 hasConceptScore W4246586307C126322002 @default.
- W4246586307 hasConceptScore W4246586307C157333092 @default.
- W4246586307 hasConceptScore W4246586307C170493617 @default.
- W4246586307 hasConceptScore W4246586307C2776112149 @default.
- W4246586307 hasConceptScore W4246586307C2780007613 @default.
- W4246586307 hasConceptScore W4246586307C2780076729 @default.
- W4246586307 hasConceptScore W4246586307C42362537 @default.
- W4246586307 hasConceptScore W4246586307C502942594 @default.
- W4246586307 hasConceptScore W4246586307C71924100 @default.
- W4246586307 hasConceptScore W4246586307C98274493 @default.
- W4246586307 hasIssue "2" @default.
- W4246586307 hasLocation W42465863071 @default.
- W4246586307 hasOpenAccess W4246586307 @default.
- W4246586307 hasPrimaryLocation W42465863071 @default.
- W4246586307 hasRelatedWork W1543124619 @default.
- W4246586307 hasRelatedWork W1601101287 @default.
- W4246586307 hasRelatedWork W2276761736 @default.
- W4246586307 hasRelatedWork W2566872566 @default.
- W4246586307 hasRelatedWork W2750699371 @default.
- W4246586307 hasRelatedWork W2946918603 @default.
- W4246586307 hasRelatedWork W2966972334 @default.
- W4246586307 hasRelatedWork W3029773958 @default.
- W4246586307 hasRelatedWork W4205728550 @default.
- W4246586307 hasRelatedWork W4362520930 @default.
- W4246586307 hasVolume "147" @default.
- W4246586307 isParatext "false" @default.
- W4246586307 isRetracted "false" @default.
- W4246586307 workType "article" @default.